MarketCapExport financials
TG Therapeutics (TGTX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
TG Therapeutics Financial Ratios 2025-2009 | TGTX
Brief overview of TG Therapeutics's valuation multiples
Ratios are assessed across five available annual reports in the 2021–2025 interval.
The latest available valuation ratios are P/E 9.69x (median 190.8x), EV/EBITDA 37.86x (median 78.88x), P/S 7.03x (median 14.91x). The current ratio basket stands about 54.2% below the five-year comparison base. Earnings and risk trends should explain the discount.
The 1/P/E calculation produces a 10.3% earnings yield. It does not capture future growth or capital structure.
Current measures of operating quality are ROE 69%, ROA 42.1%, ROCE 19%. Overall capital returns are high. The business uses resources efficiently and provides strong fundamental support for its valuation.
On PEG (0.33x), valuation is restrained relative to growth, but one ratio cannot replace cash-flow and risk analysis.
The cash conversion cycle lengthened from 37.9 days to 556.5 days, or 518.6 days. More cash is tied up in operations.
Overall picture
TG Therapeutics combines strong fundamental efficiency with valuation below its own five-year norm. The discount merits attention but should be checked against sector and financial risks.
Annual Financial Ratios TG Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
9.7 | 209.6 | 190.8 | -10.3 | -4.4 | -19.9 | -7.3 | -1.9 | -6.1 | -2.9 | -5.9 | -8.7 | -7.6 | -2.6 | -2.3 | - | - |
P/S |
7.0 | 14.9 | 10.4 | 734.7 | 228.7 | 36626.0 | 8284.6 | 2149.8 | 4765.8 | 1512.6 | 2447.4 | 3183.7 | 1024.0 | 2512.9 | - | - | - |
EPS |
3.1 | 0.2 | 0.1 | -1.6 | -2.6 | -2.4 | -2.0 | -2.3 | -1.9 | -1.6 | -1.4 | -1.6 | -0.8 | -1.4 | -0.4 | - | - |
EV (Enterprise Value) |
4.67 B | 5.08 B | 2.5 B | 2.08 B | 1.37 B | 5.12 B | 1.27 B | 344 M | 700 M | 224 M | 330 M | 436 M | 124 M | 37.9 M | -1.53 M | - | - |
EBITDA per Share |
0.85 | 0.29 | 0.15 | -1.61 | -2.61 | -2.37 | -1.91 | -2.31 | -1.91 | -1.61 | -1.38 | -1.64 | -0.794 | -1.97 | -0.458 | - | - |
EV/EBITDA |
37.9 | 121.0 | 119.9 | -9.5 | -3.8 | -18.5 | -7.0 | -1.6 | -5.6 | -2.6 | -5.0 | -7.7 | -5.8 | -1.3 | 3.3 | - | - |
PEG |
0.33 | -52.19 | -7.3 | 92.75 | -0.39 | -1.59 | -0.49 | 0.09 | 0.32 | 0.18 | -0.37 | 0.08 | -0.18 | 0.01 | 0.03 | - | - |
P/B |
6.7 | 22.1 | 15.1 | 34.9 | 6.5 | 10.7 | 32.6 | 13.6 | 10.8 | 6.4 | 3.7 | 6.1 | 3.9 | 3.1 | 0.2 | - | - |
P/CF |
-175.0 | -121.0 | -77.1 | -11.6 | -5.2 | -26.0 | -9.5 | -2.5 | -7.7 | -3.7 | -8.3 | -13.8 | -14.4 | -9.2 | -22.5 | - | - |
ROE % |
69.01 | 10.52 | 7.91 | -338.47 | -146.78 | -53.79 | -447.68 | -721.76 | -176.85 | -218.17 | -61.97 | -69.64 | -51.13 | -116.22 | -8.86 | - | - |
ROA % |
42.06 | 4.05 | 3.85 | -102.44 | -91.70 | -44.66 | -106.05 | -207.47 | -121.66 | -142.85 | -55.47 | -64.30 | -42.56 | -81.87 | -5.36 | - | - |
ROCE % |
19.03 | 18.86 | 12.86 | -372.64 | -145.38 | -52.68 | -215.18 | -389.62 | -170.99 | -208.34 | -61.37 | -68.26 | -48.26 | -129.87 | -6.22 | - | - |
Current Ratio |
2.6 | 1.6 | 1.9 | 1.4 | 2.7 | 5.9 | 1.8 | 2.0 | 3.3 | 3.0 | 8.3 | 16.6 | 6.7 | 8.3 | 6.1 | - | - |
DSO |
128.8 | 100.0 | 39.9 | 91.0 | 37.9 | - | - | 228.1 | 259.8 | 200.9 | 445.6 | 204.8 | 65.1 | - | - | - | - |
DIO |
427.7 | 712.6 | 514.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
556.5 | 812.6 | 554.2 | 91.0 | 37.9 | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
556.5 | 812.6 | 554.2 | 91.0 | 37.9 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios TG Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.05 | 0.14 | 2.69 | 0.19 | 0.03 | - | 0.03 | 0.05 | -0.07 | - | 0.8 | -0.34 | -0.28 | - | -0.26 | -0.3 | -0.51 | - | -0.65 | -0.59 | -0.69 | - | -0.73 | -0.47 | -0.48 | -0.44 | -0.69 | -0.42 | -0.43 | -0.68 | -0.43 | -0.59 | -0.59 | -0.46 | -0.48 | -0.45 | -0.52 | -0.48 | -0.5 | -0.33 | -0.28 | -0.37 | -0.28 | -0.38 | -0.35 | -0.48 | -0.51 | -0.36 | -0.25 | - | -0.16 | -0.29 | -0.17 | - | -0.16 | -0.16 | -2.03 | - | -0.01 | -0.15 | - |
EBITDA per Share |
0.15 | 0.24 | - | - | 0.06 | - | - | - | -0.06 | - | - | - | -0.26 | - | -0.26 | -0.29 | -0.5 | - | -0.64 | -0.59 | -0.68 | - | -0.72 | -0.45 | -0.48 | - | -0.68 | -0.41 | -0.43 | - | -0.44 | 0.6 | -0.59 | - | -0.48 | -0.45 | -0.52 | - | -0.51 | -0.33 | -0.29 | - | -0.29 | -0.38 | -0.36 | - | -0.51 | -0.36 | -0.25 | - | -0.17 | -0.29 | -0.17 | - | -0.17 | -0.26 | -3.43 | - | -0.01 | -0.16 | - |
ROE % |
79.25 | 80.10 | 78.72 | 18.22 | 1.34 | -0.79 | 68.35 | -51.36 | -198.24 | -191.56 | -227.20 | -327.74 | -250.56 | -107.55 | -135.04 | -119.88 | -108.84 | -68.33 | -85.11 | -67.81 | -57.16 | -36.81 | -139.28 | -282.88 | -366.48 | -447.68 | -569.28 | -550.15 | -640.02 | -721.76 | -543.74 | -449.57 | -308.24 | -176.85 | -196.79 | -218.94 | -220.95 | -218.17 | -169.51 | -113.72 | -86.23 | -61.97 | -68.10 | -76.44 | -74.57 | -69.64 | -57.55 | -52.20 | -46.41 | -36.99 | -63.26 | -69.08 | -140.02 | -130.85 | -131.14 | -107.80 | -87.37 | - | -0.30 | -2.93 | - |
ROA % |
43.92 | 44.21 | 43.58 | 7.16 | 0.28 | -0.49 | 33.92 | 11.70 | -9.89 | -7.02 | -23.46 | -73.97 | -75.19 | -55.31 | -76.21 | -76.08 | -76.50 | -53.73 | -67.66 | -55.21 | -47.07 | -30.55 | -54.83 | -78.89 | -92.65 | -106.05 | -146.19 | -148.80 | -179.37 | -207.47 | -174.75 | -166.53 | -142.86 | -121.66 | -133.19 | -146.13 | -146.04 | -142.85 | -115.15 | -81.86 | -67.91 | -55.47 | -61.62 | -69.70 | -68.45 | -64.30 | -52.11 | -45.67 | -39.49 | -30.79 | -41.95 | -41.06 | -73.84 | -66.20 | -66.38 | -57.00 | -46.46 | - | -0.18 | -1.77 | - |
ROCE % |
27.00 | 27.04 | 27.54 | 27.67 | 9.28 | 5.65 | 75.31 | -41.60 | -181.41 | -175.62 | -210.41 | -310.25 | -239.07 | -104.22 | -131.55 | -116.98 | -106.83 | -67.59 | -84.09 | -66.55 | -56.00 | -35.97 | -193.58 | -269.12 | -349.16 | -339.49 | -482.31 | -140.21 | -221.14 | -131.30 | -178.45 | -78.06 | -303.85 | -130.87 | -200.37 | -197.89 | -194.47 | -153.18 | -166.79 | -114.14 | -83.84 | -44.83 | -66.61 | -67.92 | -60.57 | -46.19 | -57.79 | -52.57 | -46.92 | -37.42 | -66.39 | -82.97 | -214.53 | -205.26 | -205.57 | -179.69 | -148.11 | - | -0.31 | -3.09 | - |
Current Ratio |
1.6 | 1.6 | 2.5 | 1.6 | 1.6 | 1.6 | 1.5 | 1.8 | 1.8 | 1.9 | 2.0 | 1.2 | 1.2 | 1.4 | 1.9 | 2.0 | 2.3 | 2.7 | 4.2 | 4.9 | 5.3 | 5.9 | 5.9 | 5.9 | 5.9 | 1.3 | 1.3 | 1.3 | 1.3 | 1.4 | 1.4 | 1.4 | 1.4 | 3.2 | 3.2 | 3.2 | 3.2 | 2.9 | 2.9 | 2.9 | 2.9 | 9.5 | 9.5 | 9.5 | 9.5 | 13.1 | 13.1 | 13.1 | 13.1 | 6.0 | 6.0 | 6.0 | 6.0 | 3.4 | 3.4 | 3.4 | 3.4 | 3.0 | 2.5 | 2.5 | 2.5 |
DSO |
150.7 | 146.4 | 140.2 | 136.3 | 120.5 | - | 108.4 | 92.3 | 83.4 | - | 15.6 | 74.1 | 50.4 | - | 42.7 | 76.1 | 51.9 | - | 52.0 | 50.3 | 44.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
306.8 | 375.8 | 490.7 | 754.0 | 787.4 | - | 810.4 | 873.4 | 985.6 | - | 829.4 | 1371.7 | 1449.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 630.9 | 890.3 | 908.0 | - | 918.8 | 965.7 | 1069.1 | - | 845.0 | 1445.8 | 1499.6 | - | 42.7 | 76.1 | 51.9 | - | 52.0 | 50.3 | 44.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 630.9 | 890.3 | 908.0 | - | 918.8 | 965.7 | 1069.1 | - | 845.0 | 1445.8 | 1499.6 | - | 42.7 | 76.1 | 51.9 | - | 52.0 | 50.3 | 44.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company TG Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Schweiz
USA
Israel
China
Canada
Britain
Russia
